Inventor
DAI PEIHONG
US13 patents
Patents
13 patentsUS10736962B2Aug 11, 2020
Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
MEMORIAL SLOAN KETTERING CANCER CENTER15 citations94
US10548930B2Feb 4, 2020
Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
MEMORIAL SLOAN KETTERING CANCER CENTER15 citations93
US10512662B2Dec 24, 2019
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
MEMORIAL SLOAN KETTERING CANCER CENTER6 citations84
US10639366B2May 5, 2020
Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
MEMORIAL SLOAN KETTERING CANCER CENTER10 citations83
US12036279B2Jul 16, 2024
Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
MEMORIAL SLOAN KETTERING CANCER CENTER2 citations73
US11986503B2May 21, 2024
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
MEMORIAL SLOAN KETTERING CANCER CENTER2 citations73
US11541087B2Jan 3, 2023
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
MEMORIAL SLOAN KETTERING CANCER CENTER2 citations73
US11285209B2Mar 29, 2022
Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
MEMORIAL SLOAN KETTERING CANCER CENTER3 citations73
US10765711B2Sep 8, 2020
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy
MEMORIAL SLOAN KETTERING CANCER CENTER2 citations73
US11253560B2Feb 22, 2022
Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
MEMORIAL SLOAN KETTERING CANCER CENTER3 citations72
US12397029B2Aug 26, 2025
Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors
MEMORIAL SLOAN KETTERING CANCER CENTER0 citations62
US11426460B2Aug 30, 2022
Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
MEMORIAL SLOAN KETTERING CANCER CENTER0 citations62
US12252702B2Mar 18, 2025
Recombinant poxviruses for cancer immunotherapy
MEMORIAL SLOAN KETTERING CANCER CENTER0 citations60